Skip to main content

Trading of Osmetech on Nasdaq Set for June 3

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Osmetech today said that suspension of trading of its shares on AIM in London could occur on Friday, and its shares would begin trading on the Nasdaq next Thursday, if the execution of its Underwriter Agreement is done before tomorrow morning.

The company announced in March its plans to float in the US, cease trading on the AIM in London, change its name to GenMark Diagnostics, and move its headquarters to Pasadena, Calif.

A UK court hearing to sanction its plans had been scheduled for Wednesday, but because of a delay in the closing of GenMark's fundraising, the hearing was delayed, resulting in a subsequent delay to the suspension of trading Osmetech shares on AIM. The day when Osmetech would begin trading on the Nasdaq and cancellation of trading on AIM also were delayed.

Today, the company said that a UK court has agreed to sanction its plan conditional upon the execution of the Underwriter Agreement by Osmetech and the underwriters before 7 a.m. BST, Friday.

If that happens, suspension of trading of Osmetech shares on AIM will take place at 7:30 a.m. Friday. Shares of GenMark stock would begin trading on the Nasdaq on June 3. Cancellation of trading on the AIM of Osmetech shares would take place the following day.

Also, Reuters today reported that Osmetech is cutting the price range for the planned US initial public offering to between $6 and $7 per share. The new price range would represent a reduction from a previously announced a range of between $8 and $10 per share. The company still plans to sell 4.5 million shares.

Reuters cited an unnamed underwriter in its story. Messages left with Osmetech officials by GenomeWeb Daily News had not been returned by the time this article was published.

Osmetech is expected to price its IPO after the close of the market today, according to the underwriter.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.